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A B S T R A C T
Prostate cancer is a multistep and complicated cancer type that is regulated by androgens at the cellular
level and remains the second commonest cause of death among men. Discovery and development of
novel chemotherapeutic agents enabling rapid tumor cell death with minimal toxic effects to healthy
tissues might greatly improve the safety of chemotherapy.
The present study evaluates the anti-cancer activity of a novel heterodinuclear copper(II)Mn(II)
complex (Schiff base) in combination with poly(ethylene oxide) and poly(propylene oxide) block
copolymer (Pluronic) P85. We used assays for cell proliferation, apoptosis, cell migration and invasion,
DNA binding and cleavage to elucidate the molecular mechanisms of action, in addition to the anti-
inﬂammatory potency of the new combination. The combined treatment of Schiff base and P85 lead to a
remarkable anti-cancer effect on prostate cancer cell lines. Cell proliferation was inhibited in Schiff base-
P85 treatment. The activity of this formulation is on DNA binding and cleavage and prevents
inﬂammation in in vitro conditions. This is the ﬁrst study presenting the anti-cancer activity of the
present Schiff base derivative and its combination with P85 to treat prostate cancer in vitro.
© 2016 Elsevier Masson SAS. All rights reserved.
1. Introduction
Prostate cancer is a multistep and complicated cancer type
which is characterized by hormone regulation at the molecular and
cellular level, and is the most common cancer with a high
prevalence [1,2]. Although androgen deprivation therapy is used as
a ﬁrst line treatment option for several years, a concomitant
chemotherapeutic treatment is often required for a successful
treatment outcome [3]. Therefore, the improvement of current
therapeutic approaches, screening of new drugs and identiﬁcation
of new agents is essential for the treatment of advanced prostate
cancer. The introduction of many novel targeted therapeutics into
clinical practice is a rapidly growing ﬁeld in medical oncology.
Cancer chemotherapy involves targeting cancer cells with cyto-
toxic agents. Chemotherapy has been considered as a solution for
the treatment of many cancers, resulting in destruction of
malignant cells, while having a nonspeciﬁc toxicity on all other
cell types. The current chemotherapeutic approach for prostate
cancer is to use single or combined chemotherapeutic agents to
increase survival rates for hormone refractory disease [4]. These
therapeutic strategies are able to devastate the tumor but are often
ineffective on advanced prostate cancer. Although the combination
of the chemotherapeutic agents is considered to be effective
against prostate cancer, there is currently no reported data
regarding the increased survival rates or improved patients life
quality [5]. Developments of new chemotherapeutic agents that
enable the inhibition of prostate cancer progression are the aim of
interest. Moreover, the impact of cytotoxic chemotherapy is not
limited to the cancer tissue. Therefore, future treatments will
include cytotoxic tools that preferentially target tumor cells.
Pluronics as an interesting class of polymeric materials
arranged in a triblock structure consisting of poly(ethylene oxide)
(PEO) and poly(propylene oxide) (PPO) units. The number of these
hydrophilic and hydrophobic units determines the micelle
characteristics and diameter of micelles carrying drug molecules
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